AstraZeneca PLC

The stock is in a constructive long-term uptrend, holding above its 200-day average and trading near the upper end of its 52-week range. That leaves the setup favoring trend continuation rather than a deep-value rebound, with the prior year’s lows well behind it.

Street sentiment is firmly positive, with a Buy consensus and a $186.67 median target that sits below the current share price but still implies a premium to many older targets. Recent changes have mostly been reiterations or upgrades held steady, while fresh targets from HSBC at $108 and Morgan Stanley at $103 show the target stack has been moving higher over time.

The next print follows a solid beat pattern: 5 of the last 7 quarters topped estimates, including a 1.6% beat in April and a 5.3% beat last November. Analysts still expect growth, with next-year EPS at 8.7231 versus 6.64 TTM, so shareholders should watch for continued execution and any guidance lift.

Recent insider activity leans to net selling, driven by one meaningful discretionary sale from an officer. The other entries are award or administrative-type transactions, which are typically noise rather than a signal on conviction.

Profitability is strong, with an 81.5% gross margin, 27.94% operating margin, and 17.19% net margin. Growth remains healthy too, with revenue up 12.5% year over year and earnings up 5.3%, while free cash flow reached $20.48 billion in the latest fiscal year.

AZN screens as a high-quality large-cap pharma name with better-than-average margins and a lower-beta profile than many healthcare peers. At 21.07x earnings, it trades at a premium to the broad sector, so the market is paying for durability and pipeline execution.